Skip to main content
AD

ADC Therapeutics

Lausanne, Switzerland
Last funding
$86.6M
Post-IPO EquityOct 2026

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

About ADC Therapeutics

How much funding has ADC Therapeutics raised?

ADC Therapeutics has raised $86.6M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2026.

Who are ADC Therapeutics's investors?

ADC Therapeutics's investors include TCG Crossover, AstraZeneca, Redmile Group, Bain Capital Life Sciences, 4BIO Capital.

Where is ADC Therapeutics headquartered?

ADC Therapeutics is headquartered in Lausanne, Switzerland.

What does ADC Therapeutics do?

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

What stage is ADC Therapeutics at?

ADC Therapeutics is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"ADC Therapeutics — Funding & Investors." VCBacked, October 8, 2026, https://www.vcbacked.co/company/adc-therapeutics. Accessed November 15, 2026.
APA
VCBacked. (2026). ADC Therapeutics — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/adc-therapeutics
Wikipedia (cite web)
{{cite web |title=ADC Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/adc-therapeutics |website=VCBacked |access-date=November 15, 2026}}

Profile data sourced and verified per the VCbacked methodology · Last funding round dated

Work at ADC Therapeutics? Request a listing update

Founder contacts
m***@adctherapeutics.com
linkedin.com/in/●●●●●●
Emails, phones & LinkedIn · 41,000+ verified contacts
Get instant access →